Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder

Author(s): Seetal Dodd, Brisa S. Fernandes, Olivia M. Dean

Journal Name: Current Neuropharmacology

Volume 13 , Issue 5 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Current pharmacological treatments for bipolar disorder (BD) are limited and efficacy has historically been discovered through serendipity. There is now scope for new drug development, focused on the underlying biology of BD that is not targeted by current therapies. The need for novel treatments is urgent when considering treatment resistant BD, where current therapies have failed. While established drugs targeting the monoamine systems continue to be worthwhile, new biological targets including inflammatory and oxidative an nitrosative pathways, apoptotic and neurotrophic pathways, mitochondrial pathways, the N-methyl-Daspartate (NMDA)–receptor complex, the purinergic system, neuropeptide system, cholinergic system and melatonin pathways are all being identified as potential anchors for the discovery of new agents. Many agents are experimental and efficacy data is limited, however further investigation may provide a new line for drug discovery, previously stalled by lack of corporate interest.

Keywords: Bipolar disorder, inflammation, nitrosative stress, oxidative stress, pathways, pharmacotherapy, receptors, treatment targets.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [656 - 662]
Pages: 7
DOI: 10.2174/1570159X13666150630175841
Price: $65

Article Metrics

PDF: 22